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Abstract
Enterococcus faecalis (E. faecalis) has become a major leading cause of nosocomial endocarditis. Treatment of such
infections remains problematic and new therapeutic options are needed. Nine E. faecalis strains were tested: six obtained
from patients presenting endocarditis, one with isolated bacteremia, and two reference strains. Antibiotics included
daptomycin, alone or in combination, linezolid, tigecycline, rifampicin, gentamicin, teicoplanin, ceftriaxone and amoxicillin.
Time-kill studies included colony counts at 1, 4 and 24 h of incubation. Significant bactericidal activity was defined as a
decrease of $3log10CFU/ml after 24 h of incubation. Antibiotics were tested at a low (10
6 CFU/ml) and high (109 CFU/ml)
inoculum, against exponential- and stationary-phase bacteria. We also performed time kill studies of chemically growth
arrested E. faecalis. Various pH conditions were used during the tests. In exponential growth phase and with a low
inoculum, daptomycin alone at 60 mg/ml and the combination amoxicillin-gentamicin both achieved a 4-log10 reduction in
one hour on all strains. In exponential growth phase with a high inoculum, daptomycin alone was bactericidal at a
concentration of 120 mg/ml. All the combinations tested with this drug were indifferent. In stationary phase with a high
inoculum daptomycin remained bactericidal but exhibited a pH dependent activity and slower kill rates. All combinations
that did not include daptomycin were not bactericidal in conditions of high inoculum, whatever the growth phase. The
results indicate that daptomycin is the only antibiotic that may be able of overcoming the effects of growth phase and high
inoculum.
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Introduction
Invasive infections with Enterococcus faecalis (E. faecalis) are
infrequent but steadily increasing, especially in elderly or
immunocompromised patients, and in the field of health-care-
associated infections [1]. The incidence of infective endocarditis is
3 to 10 per 100,000 people per year on average; 5–11% of these
infections are caused by enterococci, mainly E. faecalis (90%) [2,3].
The overall mortality of this disease is 11 to 35% [4].
Recommendations of the European Society of Cardiology (ESC)
and the Infectious Diseases Society of America (IDSA) continue to
advocate a first line therapy with amoxicillin and gentamicin for 6
weeks [4,5]. This recommendation is poorly followed by
physicians because of the cumulative toxicity of aminoglycosides
and evidence from the literature that do not support the addition
of an aminoglycoside to beta-lactam treatment of patients with
endocarditis caused by Gram-positive cocci [6]. Following the
work of Mainardi et al. [7] and Gavalda et al. [8], an alternative
treatment has appeared in the recommendations cited above with
the combination of amoxicillin and ceftriaxone. But clinical trials
that have been conducted are uncontrolled, with a small number
of patients and have not shown any improvement in mortality
[9,10]. Thus, this combination offers mostly an alternative therapy
in case of contra-indication to aminoglycosides or high-level
aminoglycoside resistance.
These observations emphasize the need to evaluate new
therapeutic options. Daptomycin is a cyclic lipopetide and belongs
to a novel class of antimicrobial agents. It has shown its efficacy in
vitro against enterococci isolates, even those resistant to glycopep-
tides [11]. Animal experiments have shown that daptomycin is
effective on endocarditis caused by susceptible and multidrug
resistant enterococci [12], particularly with the use of higher peak
concentrations obtained with the administration of 6 mg/kg once
daily, compared to 3 mg/kg every 12 hours as prescribed in the
late 1980s. Efficiency of daptomycin has been reported against
non dividing Staphylococcus aureus (S. aureus) and high inoculum
[13,14], usually observed in sequestered infections like endocar-
ditis [15], but data are lacking for enterococci. The effect of pH on
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antimicrobial activity has been reported for quinolones and
aminoglycosides against S. aureus and Pseudomonas aeruginosa
[16,17]. Lamp C et al. also demonstrated in one experiment a
pH dependent activity of daptomycin against S. aureus but high
antibiotic concentrations could overcome the inhibitory effects of
acidity [18].
Therefore, we planed to investigate in vitro activity of
daptomycin, alone or in combination, against clinical strains of
Enterococcus faecalis isolated from endocarditis. Time-kill studies
with daptomycin, alone or in combination with linezolid,
tigecycline, rifampicin, gentamicin, teicoplanin and amoxicillin
were performed at a standard (106 CFU/ml) and high (109 CFU/
ml) inoculum, against exponential and stationary growth-phase
bacteria. We also tested nondividing E. faecalis. Various pH
conditions were used during the assay and two concentrations for
daptomycin: 60 mg/ml, that is close to the peak obtained with a
6 mg/kg dosing regimen in human, and 120 mg/ml, obtained with
a higher dosage of 8 mg/kg [19]. Other antibiotics concentrations
have been chosen according to their PK/PD characteristics, the
recommended dosage regimen and the peak or trough concen-
trations obtained with it.
Materials and Methods
Bacterial strains
Nine strains were included in this study. Six strains (identified as
the strains FG, ZM, ME, OB, FAM, LH) isolated from blood
culture of patients with confirmed endocarditis according to the
Dukes modified criteria [4]. One of those strains was highly
resistant to aminoglycosides (strain FG). One strain was isolated
from blood culture without underlying endocarditis (strain CR).
Two reference strains were included in the study: JH2-2 and
ATCC11700 (CNR des ente´rocoques, Caen, France).
Antibiotics
Antibiotics as pure titrated powders were supplied by their
respective manufacturers (amoxicillin-ceftriaxone-gentamicin by
Panpharma France, linezolid and tigecycline by Pfizer France,
daptomycin by Novartis France, rifampicin by Sanofi Aventis
France). Various combinations were tested at fixed concentrations:
daptomycin alone (60 and 120 mg/ml), amoxicillin (5 mg/ml) with
ceftriaxonee (20 mg/ml), amoxicillin with gentamicin (15 mg/ml),
amoxicillin with linezolid (5 mg/ml), amoxicillin with rifampicin
(2,5 mg/ml), amoxicillin with teicoplanin (15 mg/ml), amoxicillin
with daptomycin (60 mg/ml), daptomycin (60 and 120 mg/ml)
with rifampicin (2,5 and 10 mg/ml), daptomycin (60 mg/ml) with
tigecycline (2 mg/ml), daptomycin (60 mg/ml) with linezolid (5 mg/
ml).
Medium
Mueller-Hinton broth (MBH, bioMe´rieux, France) was used for
all experiments and supplemented with calcium at a final
concentration of 50 mg/l (MHBc) due to daptomycin calcium
dependency for antimicrobial activity [20]. Final calcium concen-
trations were measured in MBHc. Nutrient restricted medium
supplemented with calcium (resMEDc) was used for optical density
adaptation of stationary growth phase E. faecalis: 1% glucose, 4%
Mueller-Hinton broth and calcium 50 mg/l in phosphate buffered
saline (NaCl 137 mmol/l, Na2HPO4 10 mmol/l, KH2PO4
2 mmol/l, pH 7,4) [10]. pH was adjusted to 5, 6 or 7 with 0,1
NaOH to a final percentage of total volume ,1%.
Susceptibility testing
The Minimal Inhibitory Concentrations (MICs) were deter-
mined by Etest (Biome´rieux, France) on Mueller-Hinton Agar
(calcium final concentration 50 mg/l) inoculated with a standard
inoculum (105 to 106 CFU/ml) according to The European
Committee on Antimicrobial Susceptibility Testing (EUCAST)
guidelines [21]. MICs were also determined with a high inoculum
(108 to 109 CFU/ml), incubated at 37uC for 24 hours.
Time kill studies
Bacteria were initially cultured for 24 hours at 37uC with 10%
CO2 on blood agar plates then subcultured on MHBc for 24 hours
at 37uC and with 10% CO2. Those cultures were considered as
stationary growth-phase bacteria and used to prepare exponential
growth phase E. feacalis at high and standard inoculum, chemically
arrested growth phase E. faecalis at standard inoculum and
stationary growth phase E. faecalis at standard and high inoculum,
as detailed below. Final bacteria suspensions were treated with
various antibiotic combinations or daptomycin alone and cultured
for 24 hours at 37uC. Culture aliquots of 100 ml were removed at
1, 4 and 24 hours and plated on agar for colony counts. A positive
bactericidal activity was defined by a $3log10 reduction in colony
counts. Model experiments were performed in triplicate to ensure
reproducibility.
Time kill studies with exponential growth-phase E.
faecalis
Stationary growth-phase E. faecalis were prepared as detailed,
resuspended in MHBc and incubated at 37uC while shaking at
250 rpm for 3 hours prior to examination. Standard inoculum of
106 CFU/ml was obtained by standardizing OD550 to 0.125
followed by a 1:100 dilution. High inoculum was obtained by
centrifugation of bacterial suspensions (50006g for 10 minutes) at
4uC. Centrifuged aliquots were then resuspended in MHBc for
exponential testing and adjusted to an OD550 of 1. Antibiotics
were then added to the bacterial suspension and colony counts
performed as detailed.
Time kill studies of stationary growth-phase E. faecalis
Initial stationary growth phase bacteria were obtained as
detailed above, OD550 standardized to 0.125 and followed by a
1:100 dilution to obtain a standard inoculum. Centrifugation
(50006g for 10 minutes) was performed and culture aliquots
resuspended in resMHBc and adjusted to an OD550 of 1 to obtain
high inoculum suspensions. Antibiotics were then added to the
bacterial suspensions and colony counts performed as detailed.
Time kill studies of chemically arrested growth E. faecalis
Exponential growth-phase E. faecalis were prepared as detailed
and inoculum adjusted to an OD550 of 0.125. Carbonyl cyanide
m-chlorphenylhydrazone (CCCP) was added at a final concen-
tration of 10 mM. Bacterial suspensions were then divided into two
portions, incubated 3 hours at 37uC while shaking
(250 rpm).OD550 was adjusted to 0.125 and followed by a 1:100
dilution for the portion used in susceptibility testing, the second
being used as control to ensure cell viability.
Statistical analysis
Changes in CFU/ml at 24 h in conditions of high inoculum
were compared by Mann-Whitney U-test. A p value of #0.05 was
considered significant. All statistical analyses were performed using
GraphPad Prism software 6.0 (GraphPad, San Diego, CA, USA).
Time Kill Studies of Daptomycin against E. faecalis
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Ethic statements
Ethical approval was waived for this study. Patient approval is
not necessarily required for the use of bacteria isolated from
clinical strains. French legislation exempts the work from requiring
it (Law nu 2004-800 August 2004 the 6th, bioethic issues).
Results
Susceptibility testing
MICs were determined by Etest for amoxicillin, ceftriaxone,
teicoplanin, linezolid, daptomycin and tigecycline (Table 1). All
strains tested were susceptible to amoxicillin, daptomycin,
teicoplanin, linezolid and resistant or intermediate for tigecycline.
In conditions of high inoculum, MICs increased 2- to 8-fold for all
antibiotics.
Exponential growth phase E. faecalis with a standard
inoculum
Daptomycin at 60 mg/ml and the combination amoxicillin-
gentamicin resulted in a 4-log decrease of the initial inoculum on
all strains except the strain with high-level aminoglycosides
resistance (strain FG) where the 4-log reduction was achieved in
4 to 24 hours (Table 2). There were no synergistic or antagonist
effect when daptomycin was associated with other antibiotics. The
combination amoxicillin-ceftriaxone was more slowly bactericidal
on 6/7 strains with a 3 to 4-log reduction in 24 hours and the
combination amoxicillin-teicoplanin was bactericidal at a 3-log
decrease level on 4/7 strains. Both amoxicillin-linezolid and
amoxicillin-rifampicin combinations were poorly bactericidal with
a 1 to 2-log decrease for 5/7 and 6/7 strains respectively.
Chemically growth arrested bacteria under a standard
inoculum
All the combinations tested, but daptomycin, showed lower kill
rates when compared to exponential growth phase bacteria
(Table 3). Daptomycin at 60 mg/ml and the combination
amoxicillin-gentamicin resulted in a 2 to 4-log reduction in 1 hour
and a 4-log reduction in 24 hours for 7/7 and 6/7 strains
respectively. No synergistic or antagonist effects could be
evidenced when daptomycin was associated with other antibiotics.
Any other combinations tested were either bacteriostatic or
ineffective on all strains, particularly the combination amoxicil-
lin-linezolid that completely lost any activity on 3/7 strains.
Exponential growth phase E. faecalis under a high
inoculum
Daptomycin alone at 60 mg/ml showed only a bacteriostatic
activity on 6/7 strains (Figure 1). Bactericidal activity was observed
with 1 strain (4-log decrease in 24 hours). Daptomycin alone at
120 mg/ml was bactericidal on 8/9 strains in 1 to 4 h with a 3 to
5-log decrease and showed only a 2-log decrease after 24 hours on
1/9 strains. No synergistic or antagonist effect could be evidenced
with any combination tested with daptomycin. The combination
amoxicillin-gentamicin resulted in a 4-log decrease on 1/9 strains,
a 2-log decrease on 2/9 strains and was totally ineffective on the 6
remaining strains. All the other combinations tested, i.e. amoxi-
cillin-ceftriaxone, amoxicillin-teicoplanin, amoxicillin-linezolid
and amoxicillin-rifampicin did not reduce initial inoculum after
24 h. Daptomycin activity at 120 mg/ml was significantly higher
than daptomycin at 60 mg/ml (p,0,0001) and than the combina-
tion amoxicillin-gentamicin (p,0,0001) (Figure 2).
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Stationary growth phase E. faecalis under a high
inoculum
Daptomycin at 60 mg/ml and pH 7, alone or in combination,
did not reduce initial inoculum for 4/9 strains and was
bacteriostatic for 5/9 strains after 24 hours (2-log reduction)
(Figure 3). Daptomycin at 120 mg/ml and pH 5 was bacteriostatic
on all strains (1 to 2-log reduction). When pH was adjusted to 6,
the activity of daptomycin at 120 mg/ml increase with a 3 to 4-log
reduction in 4 hours for 3/9 strains and a $4-log reduction for 4/
9 strains. When pH was adjusted to 7, daptomycin (120 mg/ml)
bactericidal activity was optimum. At 4 hours 5/9 strains
experienced a 2 to 4-log decrease and at 24 hours, a 3 to 6-log
reduction was evidenced for 8/9 strains. Daptomycin activity at
120 mg/ml and pH 7 was significantly higher than daptomycin at
120 mg/ml and pH 5 (p,0,0001), than daptomycin at 60 mg/ml
and pH 7 (p,0,0001), but not significantly higher than daptomy-
cin at 120 mg/ml and pH 6 (p=0,0537) (Figure 2).
Discussion
Endocarditis and bone infections are specific issues as bacteria
are sequestered, with high density (108 to 1010 bacteria per g of
tissue) and mostly nondividing cells encased in a biofilm matrix
[8,15,22]. Our data indicate that, in conditions of high inoculum
and with stationary growth phase E. faecalis, daptomycin is the only
antibiotic tested that remains efficient. The bactericidal activity at
120 mg/ml seems to be pH dependent. Daptomycin has been
authorised by FDA with a maximum dosage of 6 mg/kg that
usually leads to a peak concentration of 85 to 95 mg/ml, whereas a
dosage of 8 mg/kg can lead to peak concentrations from 110 to
120 mg/ml [19,23]. Recent data from clinical trials in healthy
subjects or retrospective analysis from infected patients suggest
that daptomycin could be used at doses greater than 6 mg/kg, up
to 12 mg/kg, with a good safety [24,25]. Thus, next in vitro studies,
animal experiments or clinical trials in the field of endocarditis or
bone infections should probably consider higher dosage leading to
higher concentrations of daptomycin. This consideration is also
supported by the emergence of daptomycin resistance in
Staphylococcus sp. and Enterococcus sp. Development of daptomycin
resistance in methicillin-resistant S. aureus has been observed
following vancomycin-unresponsive S. aureus bacteremia or oste-
omyelitis [26]. Similar observations with enterococci remain rare
but clinicians should be aware of this possibility [27,28]. Our study
shows increased MICs for daptomycin in conditions of high
inoculum even if all the strains would remain susceptible according
to current breakpoints [21]. Emergence of enterococci with higher
Figure 1. Time kill studies with 9 strains of Enterococcus faecalis with a high inoculum and exponential growth phase bacteria. Nine
strains of Enterococcus faecalis were used, including: 6 clinical strains obtained from patients presenting endocarditis (OB, FAM, ME, LH, FG, ZM); 1
clinical strain obtained from enterococcus bacteriemia without endocarditis (CR) and 2 reference strains (JH2-2, ATCC 11700). Daptomycin alone at
120 mg/ml (B) was bactericidal on 8/9 strains in 1 to 4 h with a 3 to 5-log decrease and showed only a 2 log decrease after 24 hours on 1/9 strains;
whereas daptomycin alone at 60 mg/ml (A) and the combination amoxicillin-gentamicin were mainly not bactericidal (C).
doi:10.1371/journal.pone.0064218.g001
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Figure 2. Daptomycin activity against nine strains of Enterococcus faecalis with a high inoculum and exponential or stationary
growth phase bacteria, statistical analysis. Nine strains of Enterococcus faecalis were used, including: 6 clinical strains obtained from patients
presenting endocarditis (OB, FAM, ME, LH, FG, ZM); 1 clinical strain obtained from enterococcus bacteriemia without endocarditis (CR) and 2 reference
strains (JH2-2, ATCC 11700). In conditions of high inoculum and with exponential growth phase bacteria daptomycin activity at 120 mg/ml was
significantly higher than daptomycin at 60 mg/ml (p,0,0001) and than the combination amoxicillin-gentamicin (p,0,0001) (A). In conditions of high
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MICs means higher mutant prevention concentration (MPC) and
higher AUC0–24 required to meet the AUC0–24/MIC target, the
PK/PD parameter predictive of efficacy. The use of higher
dosage, that produce higher peak concentrations and AUC0–24,
should be able to reach MPC even in condition of high inoculum,
and optimize AUC0–24/MIC [29]. In a recently published in vitro
pharmacokinetic/pharmacodynamic model with simulated endo-
cardial vegetations, Ashley D. Hall et al. have shown that
vancomycin-resistant E. faecalis developed reduced daptomycin
susceptibility with daptomycin at 6, 8 and 10 mg/kg/day but not
at 12 mg/kg/day. Additionally, bactericidal activity was sustained
over 96 hours with daptomycin at 10 and 12 mg/kg/day regimens
but not with the 6 and 8 mg/kg/day regimens [30].
Previous in vitro and animal studies have identified synergistic
effects of daptomycin with rifampicin, ampicillin or gentamicin on
enterococci and staphylococci. In vitro studies have shown 57% to
88% synergistic effect on enterococci with rifampicin by agar
diffusion, chequerboard or time-kill studies [31]. Animal models of
infection have focused on S. aureus, mainly MRSA infections. Data
are promising in experimental osteomyelitis and foreign body
infections but remain controversial for experimental endocarditis
[22,32,33]. In clinical practice, rifampicin is commonly used in
combination for bone and joint infections, or endocarditis on
prosthetic valves where it is recommended in first line therapy for
staphylococci [4]. It penetrates the biofilm matrix, and combina-
tion with daptomycin could prevent the emergence of rifampicin
resistance [34,35]. Our in vitro study failed to show any synergistic
inoculum and with stationary growth phase bacteria daptomycin activity at 120 mg/ml and pH 7 was significantly higher than daptomycin at 120 mg/
ml and pH 5 (p,0,0001), than daptomycin at 60 mg/ml and pH 7 (p,0,0001), but not significantly higher than daptomycin at 120 mg/ml and pH 6
(p=0,0537). Median changes in CFU/ml at 24 h were compared by Mann-Whitney U-test. A p value of #0.05 was considered significant. All statistical
analyses were performed using GraphPad Prism software 6.0 (GraphPad, San Diego, CA, USA).
doi:10.1371/journal.pone.0064218.g002
Figure 3. Time kill studies with 9 strains of Enterococcus faecalis with a high inoculum and stationary growth phase bacteria. Nine
strains of Enterococcus faecalis were used, including: 6 clinical strains obtained from patients presenting endocarditis (OB, FAM, ME, LH, FG, ZM); 1
clinical strain obtained from enterococcus bacteriemia without endocarditis (CR) and 2 reference strains (JH2-2, ATCC 11700). Daptomycin at 120 mg/
ml and pH 5 (A) was bacteriostatic on all strains (1 to 2-log reduction). When pH was adjusted to 6 (B), the activity of daptomycin at 120 mg/ml
increase with a 3 to 4-log reduction in 4 hours for 3/9 strains and a $4-log reduction for 4/9 strains. When pH was adjusted to 7 (C), daptomycin
(120 mg/ml) bactericidal activity was optimum. At 4 hours 5/9 strains experienced a 2 to 4-log decrease and at 24 hours, a 3 to 6-log reduction was
evidenced for 8/9 strains. Daptomycin at 60 mg/ml and pH 7 (D), alone or in combination did not reduce initial inoculum for 4/9 strains and was
bacteriostatic for 5/9 strains after 24 hours (2-log reduction).
doi:10.1371/journal.pone.0064218.g003
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effects between daptomycin and all the other antibiotics tested,
particularly in conditions of high inoculum and with stationary
growth phase bacteria where rifampicin was used at 2,5 mg/ml
and 10 mg/ml with daptomycin at 60 mg/ml and 120 mg/ml. In
conditions of standard inoculum and with exponential growth
phase bacteria daptomycin alone achieved a 4 log10 reduction
when the first colony count was performed at 1 h, reaching the
limit of detection with the method described. As a consequence, a
potential synergistic effect with tigecycline, rifampicin and line-
zolid could not be evidenced with this method.
Our study has also shown a pH dependent activity of
daptomycin. Lamp K. et al. have previously reported the same
observation on S. aureus strains where increasing pH increased
activity of daptomycin [18]. Daptomycin mechanism of action
may help understand this phenomenon. Daptomycin inhibits
formation of peptidoglycan by inhibiting transport of amino acid
precursor that is pH dependent. Our results show that daptomy-
cin, in conditions of high inoculum and with stationary growth
phase bacteria, is bacteriostatic at pH 5, partially bactericidal at
pH 6 and fully bactericidal at pH 7. This data is important for in
vitro studies with daptomycin that should monitor the pH closely to
determine correctly this antibiotic efficiency. In vivo sensitivity to
daptomycin is also probably pH dependent, an interesting data for
the treatment of bone infections where acidic pH is already
problematic for the use of aminoglycosides. Clinical reports and
literature reviews have shown the eventual efficacy of daptomycin
in such infections [36,37]. These conflicting data with those from
in vitro observations show once again that our in vitro observations
cannot be extrapolated to clinical scale. More, one has to remind
that daptomycin remains bactericidal on high inoculum, stationary
growth phase bacteria, and bacteria embedded in biofilm what is
likely to occur in prosthetic and bone infections. Additional in vitro
studies will be needed to better understand the mechanisms
involved, such as those involved in the action of aminoglycosides
on intracellular bacteria and in acidic environments [38].
Our study has limitations. We have used high concentrations of
daptomycin as some data indicate that daptomycin activity is not
limited to the drug free-fraction [39,40]. Nevertheless, concentra-
tions used in our experiments correspond to peak level concen-
trations but such levels are not maintained throughout the dosing
interval in vivo, as they are in the in vitro time kill testing.
Therapy of enterococcal endocarditis due to amoxicillin
sensitive, aminoglycosides sensitive or highly resistant strains
remain controversial. Recommendations of the European Society
of Cardiology (ESC) or the Infectious Diseases Society of America
(IDSA) still recommend a first line therapy with amoxicillin and
gentamicin for 6 weeks that is poorly followed by physicians. The
efficiency of daptomycin on enterococcal infections has been
proved in vitro, in animal infection models and our study gives
positive results on high inoculum and stationary growth phase E.
faecalis. Additional animal models should be considered now to
confirm these data.
(This work was presented in part as a poster at the 51st
Interscience Conference on Antimicrobial Agents and Chemo-
therapy, Chicago, 17 to 20 September 2011, presentation number
E-1314)
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